Event Abstract Back to Event Peripheral nerve-specific extracellular matrix hydrogel supports repair after peripheral nerve injury Travis Prest1, 2, Meghan Wyatt1, Dhruv Srinivasachar1 and Bryan N. Brown1, 2, 3 1 University of Pittsburgh, Department of Bioengineering, United States 2 University of Pittsburgh, McGowan Institute for Regenerative Medicine, United States 3 Cornell University, Department of Biomedical Engineering, United States Introduction: Peripheral nerve injury commonly results in loss of neuromuscular function, often resulting in significant impact upon both quality of life and cost of care for patients. Surgical reconstruction of damaged peripheral nerves is possible, but recovery is slow and unpredictable and restoration of function is often incomplete. An easily injectable material in an off the shelf formulation which speeds and/or improves return to function would significantly improve quality of life for affected patients and result in a significant reduction of cost associated with chronic care related to their condition. Rather than attempting to engineer a complex microenvironment, an alternative would be to use the natural microenvironment of a healthy peripheral nerve through decellularization. We believe that a peripheral nerve specific extracellular matrix hydrogel (PNS-ECM) will provide a tissue-specific microenvironment which is conducive to nerve repair, including: nerve specific growth factors that are chemotactic signals for Schwann cells, promote neurite outgrown, and provide immune modulatory activity. Materials and Methods: Porcine sciatic nerve was decellularized to generate PNS-ECM using a previously described method [1]. PNS-ECM was compared in vitro to small-intestinal submucosa matrix (SIS) and urinary bladder matrix (UBM). Experiments included nerve specific growth factor ELISAs, neurite outgrowth, and Schwann cell migration assays. ). Neurite outgrowth performed using primary spinal cord neurons collected from E14 embryonic rat pups. Media was supplemented with PNS-ECM at low concentrations (125, 250, or 500 μg/ml), pepsin (50 μg/ml, negative control), or nerve growth factor (NGF 50 pg/ml, positive control). Schwann cell migration was performed using a boyden chamber with serum supplemented media with 50 or 100 pg/mg NGF as a positive control and negative controls were serum free media with pepsin and ECM supplemented on cell side only. The PNS-ECM was then used as a lumen filler during the repair of critical length gap nerve injury in a rodent sciatic nerve. Animals were sacrificed at days 7, 14, 28, and 90 and the nerves and gastrocnemius were harvested in %10 NBF. Nerves were investigated for macrophage involvement and potential phenotypic changes caused by PNS-ECM as well as the effect on the rate of outgrowth of Schwann cells and axons across a 15 mm nerve gap. Slides of the nerve were stained for axons (β-tubulin III), Schwann cells (S-100), and M1 (CD86), M2 (CD206), and pan (CD68) macrophage markers. Muscles sections were stained with collagen V and muscle fiber diameter was measured. Results and Discussion: PNS-ECM has a similar nerve specific growth factor profile to healthy nerve tissue, including high levels of nerve growth factor (NGF; PNS-ECM 6.1±0.6 pg/mg, healthy nerve 6.0±0.8 pg/mg), brain derived neurotrophic factor (BDNF; PNS-ECM 8.8±1.1 pg/mg, healthy nerve 10.8±0.6 pg/mg), and ciliary neurotrophic factor (CNTF; PNS-ECM 10.2±0.5 pg/mg, healthy nerve 10.2±0.4 pg/mg). SIS and UBM were dissimilar to native nerve except for SIS and BDNF (SIS 8.4±1.5 pg/mg and UBM and NFG (UBM 4.7±0.5 pg/mg). Outgrowth of cells supplemented with higher concentrations of PNS-ECM (250 and 500 μg/ml) were as much as 40% greater than negative control and the application of PNS-ECM showed a dose dependent effect that at 500 μg/ml promoted 80% of positive control. PNS-ECM produced similar migration to positive controls (serum supplemented media, with 50 ng/ml NGF, and with 100 ng/ml NGF). Treatment was statistically greater than negative controls (pepsin and PNS-ECM on cell side only). In vivo preliminary data suggest the use of PNS-ECM produced a more robust connective tissue bridge during the first weeks post-surgery. Axon migration into the connective tissue bridge appears to be enhanced by PNS-ECM compared to saline control. PNS-ECM groups have significantly less atrophy at 28 and 90 days (48±2, 68±1) than saline control (59±2, 75±1). Conclusions: In vitro experiments show chemotactic bioactivity of the PNS-ECM degradation products. Animal results suggest that treatment with PNS-ECM gel improved outcomes metrics after repair of a critical length defect.
Read full abstract